Abstract: Apparatus is provided and an IDA method is modified to detect and separately dissociate alkali-metal adducts of a compound. An ion source device ionizes one or more compounds of a sample, producing an ion beam. A mass filter selects a mass range of precursor ions from the ion beam, a mass analyzer measures intensities and m/z values of the precursor ions, and one or more of the precursor ions are selected for a peak list. For each pair of precursor ions of the peak list, if an m/z difference between the pair corresponds to an m/z difference between an alkali metal ion and another alkali metal ion or a proton, an ExD device is used to dissociate one precursor ion or both precursor ions of the pair using the processor. A CID device is used to dissociate all other precursor ions of the peak list.

Abstract: A Proton Computer Tomography (pCT) system comprising: a position tracker, able to reconstruct the proton trajectory within the body; an energy detector, able to reconstruct the proton energy; wherein, the position tracker is made up of four Depleted Monolithic Active Pixel Sensors (DMAPS) placed in pairs at either side of a phantom, and the energy detector is a Super Thin Range Telescope located downstream comprising a plastic-scintillator made of layers of thin polystyrene bars oriented in alternate axis, perpendicular to the proton beam.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: This invention concerns the field of sample identification, in particular a method and apparatuses for identifying or discriminating biological species from non biological species, both as individual particles and as components of a composition, by pump-probe fluorescence spectroscopy for time-resolved detection or imaging. The method uses the finding that the UV-induced fluorescence of biological molecules is varied, in particular is depleted, by the addition of visible radiation, whereas this does not occur with non-biological organic molecules. The invention discriminates the fluorescence signals of bio and non-bio particles or species using a differential approach, i.e. the comparison. of the total fluorescence recorded with and without additional visible radiation. This allows to discriminate biological particles comprising aromatic amino-acids (AA), like peptides, proteins, bacteria, viruses, pollens, spores, etc.

Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test com

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: This invention relates to a method of producing a modified (poly)peptide, said method comprising the step of modifying in an organic solvent a crown ether-bound (poly)peptide at one or more carboxylic groups by esterification or thioesterification and/or at the amino group of the N-terminal amino acid by amidation or alkylation. Furthermore provided are (poly)peptides and antibodies obtainable with the method of the invention as well as medical uses thereof.

Abstract: This invention relates to modulators of NADPH oxidase as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing. Such modulators preferably act by inhibiting NADPH oxidase activity, wherein the NADPH oxidase comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity. Also provided are pharmaceutical compositions, medical uses and diagnostic uses of compounds of the invention.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: A method and apparatus for protection of products and packaging against counterfeiting using dedicated authentication protocol coupled with portable devices. It is based on the product identification information, i.e., PIN, generated by the product manufacturer, stored in the product database and added to product or packaging in an open and/or a hidden form. The open part is directly available to the consumer before buying, opening or consuming the product or package or damaging its integrity while the hidden part is only revealed after these operations. The hidden information can also be disappearing after a predefined interval of time or number of trials or usages. Both parts are communicated to the authentication server in a predefined order to verify the product or package authenticity. The presence, absence, or multiple requests for the same product PIN, confirm or reject product authenticity or detect attempt at attacking the system or using counterfeited products.

Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.

Abstract: The present invention is a method and apparatus for protection of products and packaging against counterfeiting using dedicated authentication protocol coupled with portable devices. It is based on the product identification information, i.e., PIN, generated by the product manufacturer, stored in the product database and added to product or packaging in an open and/or a hidden form. The open part is directly available to the consumer before buying, opening or consuming the product or package or damaging its integrity while the hidden part is only revealed after these operations. The hidden information can also be disappearing after a predefined interval of time or number of trials or usages. Both parts are communicated to the authentication server in a predefined order to verify the product or package authenticity. The presence, absence, or multiple requests for the same product PIN, confirm or reject product authenticity or detect attempt at attacking the system or at using counterfeited products.

Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test com

Abstract: The present invention is directed to a collimator that comprises grooves or channels in the submicrometer to micrometer range. The present invention is also related to uses of a collimator and collimator holder as described herein as well as apparatuses comprising the same.

Abstract: Nucleic acids that encode Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, are described.

Abstract: We prepared a transgene comprising human HB-EGF precursor cDNA, as a diphtheria toxin receptor gene, at the downstream of an insulin promoter, and introduced this transgene into a mouse fertilized egg, to produce a transgenic mouse of the present invention. In this mouse, human HB-EGF precursors are expressed specifically in islet beta cells, and by injection of diphtheria toxin, islet beta cells are selectively destroyed, resulting in that the mouse shows diabetes two or three days after the injection. This mouse can be utilized in screening and development of new medicines and therapy protocols for diabetes.

Abstract: Tumor Necrosis Factor Related Ligand (TRELL) polypeptides, a novel member of the tumor necrosis factor family (TNF) and compositions comprising them are disclosed.

Abstract: The present invention relates to Tumor necrosis factor related ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.

Abstract: The present invention relates to Tumor Necrosis Factor Related Ligand (TRELL), a novel member of the tumor necrosis factor family (TNF), modified TRELL, and pharmaceutical compositions comprising them.